JP2017000144A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017000144A5 JP2017000144A5 JP2016131637A JP2016131637A JP2017000144A5 JP 2017000144 A5 JP2017000144 A5 JP 2017000144A5 JP 2016131637 A JP2016131637 A JP 2016131637A JP 2016131637 A JP2016131637 A JP 2016131637A JP 2017000144 A5 JP2017000144 A5 JP 2017000144A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- fvii
- seq
- linker
- represented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020001507 fusion proteins Proteins 0.000 claims 14
- 102000037865 fusion proteins Human genes 0.000 claims 14
- 102100023804 Coagulation factor VII Human genes 0.000 claims 11
- 108010023321 Factor VII Proteins 0.000 claims 11
- 229940012413 factor vii Drugs 0.000 claims 11
- 102000004338 Transferrin Human genes 0.000 claims 5
- 108090000901 Transferrin Proteins 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 239000012581 transferrin Substances 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 4
- 108091005804 Peptidases Proteins 0.000 claims 3
- 239000004365 Protease Substances 0.000 claims 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 108091008146 restriction endonucleases Proteins 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108010048049 Factor IXa Proteins 0.000 claims 1
- 108010054265 Factor VIIa Proteins 0.000 claims 1
- 108010074860 Factor Xa Proteins 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 230000035602 clotting Effects 0.000 claims 1
- 229940012414 factor viia Drugs 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2010-0052719 | 2010-06-04 | ||
| KR20100052719 | 2010-06-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013513120A Division JP6143297B2 (ja) | 2010-06-04 | 2011-06-07 | 第vii因子活性を有する融合タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017000144A JP2017000144A (ja) | 2017-01-05 |
| JP2017000144A5 true JP2017000144A5 (cg-RX-API-DMAC7.html) | 2017-04-27 |
| JP6422918B2 JP6422918B2 (ja) | 2018-11-14 |
Family
ID=45067214
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013513120A Expired - Fee Related JP6143297B2 (ja) | 2010-06-04 | 2011-06-07 | 第vii因子活性を有する融合タンパク質 |
| JP2016131637A Expired - Fee Related JP6422918B2 (ja) | 2010-06-04 | 2016-07-01 | 第vii因子活性を有する融合タンパク質 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013513120A Expired - Fee Related JP6143297B2 (ja) | 2010-06-04 | 2011-06-07 | 第vii因子活性を有する融合タンパク質 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9644197B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2576625B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6143297B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101331101B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN103068854A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2011262494B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112012030941A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2801223C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2676874T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX348567B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2585231C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011152694A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201300066B (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101331101B1 (ko) | 2010-06-04 | 2013-11-19 | 에스케이케미칼주식회사 | 인자 vii 활성을 갖는 융합 단백질 |
| ES2630031T3 (es) * | 2010-09-28 | 2017-08-17 | Aegerion Pharmaceuticals, Inc. | Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada |
| US20140056870A1 (en) * | 2012-08-27 | 2014-02-27 | Allergan, Inc. | Fusion proteins |
| US20160060612A1 (en) | 2013-02-25 | 2016-03-03 | Sk Chemicals Co., Ltd. | Method of Isolating and Purifying Fusion Protein Comprising Factor VII |
| KR102058864B1 (ko) | 2013-12-16 | 2019-12-24 | 주식회사 티움바이오 | 인자 vii의 융합 단백질을 포함하는 안정성이 개선된 약학적 조성물 |
| EP3351263A1 (en) | 2017-01-20 | 2018-07-25 | Universitätsklinikum Hamburg-Eppendorf | Pharmaceutical preparation for treating or preventing tissue adhesion |
| ES3008982T3 (en) | 2017-08-18 | 2025-03-25 | Neutrolis Inc | Engineered dnase enzymes and use in therapy |
| EP3864147A4 (en) | 2018-10-08 | 2022-07-06 | Neutrolis, Inc. | DNASE ENZYME ENGINEERING FOR MANUFACTURING AND THERAPY |
| US10988746B2 (en) | 2018-10-08 | 2021-04-27 | Neutrolis, Inc. | Manufacturing and engineering of DNASE enzymes for therapy |
| CN110218259B (zh) * | 2019-06-24 | 2022-09-16 | 王跃驹 | 植物生产胰高血糖素样肽-1短肽与转铁蛋白的融合蛋白制造口服降糖胶囊的应用 |
| CN110229237A (zh) * | 2019-06-24 | 2019-09-13 | 王跃驹 | 植物生产口服epo与转铁蛋白融合蛋白胶囊的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| RU2278123C2 (ru) | 2000-02-11 | 2006-06-20 | Максиджен Холдингз Лтд. | Молекулы, подобные фактору vii или viia |
| US7176278B2 (en) * | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
| WO2003020746A1 (en) * | 2001-08-30 | 2003-03-13 | Biorexis Pharmaceutical Corporation | Modified transferrin fusion proteins |
| US8129504B2 (en) | 2001-08-30 | 2012-03-06 | Biorexis Technology, Inc. | Oral delivery of modified transferrin fusion proteins |
| CN101177456A (zh) * | 2001-08-30 | 2008-05-14 | 比奥雷克西斯药物公司 | 经修饰的运铁蛋白融合蛋白 |
| US7125843B2 (en) * | 2001-10-19 | 2006-10-24 | Neose Technologies, Inc. | Glycoconjugates including more than one peptide |
| ES2323056T3 (es) | 2002-05-01 | 2009-07-06 | Bayer Schering Pharma Aktiengesellschaft | Anticuerpos dirigidos contra factor tisular como anticoagulantes. |
| JP4873860B2 (ja) * | 2002-08-30 | 2012-02-08 | バイオレクシス ファーマシューティカル コーポレーション | 改変トランスフェリン融合タンパク質 |
| US20070072271A1 (en) * | 2004-01-07 | 2007-03-29 | Novo Nordisk Healthcare A/G | Method for the production of recombinant proteins |
| US8178495B2 (en) | 2008-06-27 | 2012-05-15 | Duke University | Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide |
| EP1816201A1 (en) * | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| ES2987558T3 (es) * | 2006-03-24 | 2024-11-15 | Bioverativ Therapeutics Inc | PC5 como enzima de procesamiento de propéptido de factor IX |
| GB0614780D0 (en) * | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
| WO2009086132A2 (en) | 2007-12-20 | 2009-07-09 | University Of Southern California | Design of spacers to increase the expression of recombinant fusion proteins |
| CN102647945B (zh) * | 2009-12-08 | 2015-07-29 | 皇家飞利浦电子股份有限公司 | 用于校正示踪剂摄取测量结果的方法和校正系统 |
| KR101331101B1 (ko) | 2010-06-04 | 2013-11-19 | 에스케이케미칼주식회사 | 인자 vii 활성을 갖는 융합 단백질 |
-
2011
- 2011-06-07 KR KR1020110054573A patent/KR101331101B1/ko active Active
- 2011-06-07 CN CN2011800277076A patent/CN103068854A/zh active Pending
- 2011-06-07 BR BR112012030941A patent/BR112012030941A2/pt not_active Application Discontinuation
- 2011-06-07 RU RU2012157301/10A patent/RU2585231C2/ru active
- 2011-06-07 AU AU2011262494A patent/AU2011262494B2/en active Active
- 2011-06-07 MX MX2012013807A patent/MX348567B/es active IP Right Grant
- 2011-06-07 WO PCT/KR2011/004131 patent/WO2011152694A2/en not_active Ceased
- 2011-06-07 CN CN201710403215.1A patent/CN107188970A/zh active Pending
- 2011-06-07 US US13/701,333 patent/US9644197B2/en not_active Expired - Fee Related
- 2011-06-07 CA CA2801223A patent/CA2801223C/en active Active
- 2011-06-07 JP JP2013513120A patent/JP6143297B2/ja not_active Expired - Fee Related
- 2011-06-07 EP EP11790052.2A patent/EP2576625B1/en active Active
- 2011-06-07 ES ES11790052.2T patent/ES2676874T3/es active Active
-
2013
- 2013-01-03 ZA ZA2013/00066A patent/ZA201300066B/en unknown
-
2016
- 2016-03-25 US US15/080,757 patent/US10696960B2/en active Active
- 2016-07-01 JP JP2016131637A patent/JP6422918B2/ja not_active Expired - Fee Related